Hypercalcemia as a biomarker of myeloproliferative neoplasms?

Authors

  • Stephen E. Langabeer Cancer Molecular Diagnostics, St. James’s Hospital, Dublin, Ireland Phone: +353-1-4103576, Fax: +353-1-4103513, E-mail: slangabeer@stjames.ie

DOI:

https://doi.org/10.17179/excli2019-1765

Keywords:

hypercalcemia, myeloproliferative neoplasms, molecular diagnostics

Downloads

Published

2019-09-03

How to Cite

Langabeer, S. E. (2019). Hypercalcemia as a biomarker of myeloproliferative neoplasms?. EXCLI Journal, 18, 777–778. https://doi.org/10.17179/excli2019-1765

Issue

Vol. 18 (2019)

Section

Letters to the editor

License

Authors who publish in this journal agree to the following terms:

  • The authors keep the copyright and grant the journal the right of first publication under the terms of the Creative Commons Attribution license, CC BY 4.0. This licencse permits unrestricted use, distribution and reproduction in any medium, provided that the original work is properly cited.
  • The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
  • Because the advice and information in this journal are believed to be true and accurate at the time of publication, neither the authors, the editors, nor the publisher accept any legal responsibility for any errors or omissions presented in the publication. The publisher makes no guarantee, express or implied, with respect to the material contained herein.
  • The authors can enter into additional contracts for the non-exclusive distribution of the journal's published version by citing the initial publication in this journal (e.g. publishing in an institutional repository or in a book).